| Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908) |
|---|
| 05/06/2004 | WO2004009585A3 Acyloxypyrrolidine derivatives and use thereof as ligands of v1b or both v1b and v1a receptors |
| 05/06/2004 | WO2004004750A3 Use of alanyl-aminopeptidase inhibitors and pharmaceutical compositions containing said inhibitors |
| 05/06/2004 | WO2003105893A3 Probiotic therapies using lactobacillus reuteri |
| 05/06/2004 | WO2003101376A3 Topical use of at least one double-stranded rna oligonucleotide (ds rna) |
| 05/06/2004 | WO2003051365A9 Use of compounds of the benzamide family as immunosuppressant |
| 05/06/2004 | WO2002089800A3 N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| 05/06/2004 | WO2002083240A9 Aromatase inhibition to enhance assisted reproduction |
| 05/06/2004 | US20040087652 Induction cell differentiation; apoptosis |
| 05/06/2004 | US20040087630 Combinations |
| 05/06/2004 | US20040087624 Analgesics; antiinflammatory agents; immunology; bone disorders; neurodegradation diseases |
| 05/06/2004 | US20040087623 Pyrazole derivatives against tgf overexpression |
| 05/06/2004 | US20040087548 Anticancer agents and treating immune disorders |
| 05/06/2004 | US20040086942 Comprises peptide mimetic which competes for binding site of immunoglobulin receptor and prevents and treats allergic disorders |
| 05/06/2004 | US20040086502 Has a binding affinity for a target antigen which is at least about two fold stronger than the binding affinity of the parent antibody for said antigen |
| 05/06/2004 | EP1415986A1 Spiro compounds |
| 05/06/2004 | EP1415653A2 Use of progesterone or an agonist thereof for the inhibition of steroid synthesis |
| 05/06/2004 | EP1414856A2 Modified calcitonin |
| 05/06/2004 | EP1414809A1 Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation |
| 05/06/2004 | EP1414808A1 1,2,4-triazin-3,5-diones as gonadotropin-releasing hormone receptor (gnrh) antagonists |
| 05/06/2004 | EP1414804A1 Acylsemicarbazides and their use as cyclin dependent kinase (cdk) inhibitors |
| 05/06/2004 | EP1414775A2 Novel bicyclic and tricyclic cannabinoids |
| 05/06/2004 | EP1414486A2 Use of glp-2 in combination with another therapeutic agent in bone-related and nutrition-related disorders |
| 05/06/2004 | EP1414469A2 Formulation containing (lyso-) phosphatidylserine for the prevention and treatment of stress states in warm-blooded animals |
| 05/06/2004 | EP1414443A1 BENZIMIDAZO 4,5-f]ISOQUINOLINONE DERIVATIVES |
| 05/06/2004 | EP1414440A1 N-phenylpyrrole guanidine derivatives as melanocortin receptor ligands |
| 05/06/2004 | EP0775155B1 Estra-1,3,5(10)-triene derivatives, methods of preparing such compounds and pharmaceutical compositions containing them |
| 05/06/2004 | CA2502607A1 Method for treating erectile dysfunction and increasing libido in men |
| 05/06/2004 | CA2502453A1 Angiogenesis inducer |
| 05/06/2004 | CA2500640A1 Vitamin d analogues, compositions comprising said analogues and their use |
| 05/05/2004 | CN1494543A Substituted benzofuran-2-carboxamides derivatives |
| 05/05/2004 | CN1494542A 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin II receptor antagonists |
| 05/05/2004 | CN1494541A Heterocyclic inhibitors of ERK 2 and uses thereof |
| 05/05/2004 | CN1148351C Compound for curing vascular complication, its preparing method and treating use |
| 05/05/2004 | CN1148191C Contraceptive compositions and preparation process thereof |
| 05/05/2004 | CN1148180C Compounds for treatment of estrogen-dependent illnesses and methods for making and using same |
| 05/04/2004 | US6730695 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for V1b and V1a arginine-vasopressin receptors |
| 05/04/2004 | US6730690 Delaying the onset or reducing the risk of developing atherosclerosis in a human patient comprising administering to said patient an effective amount of a compound of invention and an hmg-coa reductase inhibitor |
| 05/04/2004 | US6730677 Treating memory impairment; enhance excitatory synaptic activity in order to restore an imbalance between brain subregions, as in treatment of schizophrenia or schizophreniform behavior. |
| 05/04/2004 | US6730324 Biofunctional hydroxyapatite coatings and microspheres for in-situ drug encapsulation |
| 05/04/2004 | US6730288 Lower level of occlusive agent; greater drug skin penetration |
| 04/29/2004 | WO2004035058A1 Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms |
| 04/29/2004 | WO2004035050A1 Use of epothilone derivatives for the treatment of hyperparathyroidism |
| 04/29/2004 | WO2004035035A1 Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms |
| 04/29/2004 | WO2004000230A3 Cyclothiocarbamative derivatives as pr modulators and use thereof for treatment of skin disorders |
| 04/29/2004 | WO2003086282A3 Nitric oxide donors, compositions and methods of use |
| 04/29/2004 | WO2003020949A3 Targeted nucleic acid constructs and uses related thereto |
| 04/29/2004 | WO2003009807A3 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods |
| 04/29/2004 | WO2002070669A3 Secreted proteins |
| 04/29/2004 | US20040082625 Osteoporosis, bone disorders |
| 04/29/2004 | US20040082602 Kinase inhibitor; analgesics; antiarthritic agents; antihistamines; gastrointestinal disorders |
| 04/29/2004 | US20040082597 Use of CRF antagonists and related compositions |
| 04/29/2004 | US20040082592 Metabotropic glutamate receptor antagonists |
| 04/29/2004 | US20040082588 Controlling concentration of calcium in blood |
| 04/29/2004 | US20040082556 Inhibitors of type 5 and type 3 17beta-hydroxysteroid dehydrogenase and methods for their use |
| 04/29/2004 | US20040082507 Use of GLP-1 and GLP-2 peptides |
| 04/29/2004 | US20040082499 Perturbed membrane-binding compounds |
| 04/29/2004 | US20040082497 For treatment of growth hormone deficiency/polycystic ovary syndrome autoimmune/inflammatory disease |
| 04/29/2004 | US20040081971 Gastrointestinal disorders; cardiovascular disorders; autoimmune diseases; cell proliferation; antiinflammatory agents |
| 04/29/2004 | US20040081693 Capable of releasing the drug at a constant rate following zero order kinetics for 24 hours or more |
| 04/29/2004 | US20040081688 Comprising a drug, a lipid matrix and a surfactant characterized in that said drug is a peptide or a protein and lipid matrix has a monoglyceride content which is at least 70% w/w |
| 04/29/2004 | US20040081624 Mixture containing high volatility carrier; vaporization; mixing with air |
| 04/29/2004 | CA2588083A1 Selective androgen receptor modulators and methods of use thereof |
| 04/29/2004 | CA2502032A1 Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms |
| 04/29/2004 | CA2502021A1 Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms |
| 04/28/2004 | EP1413576A2 Substituted imidazole derivatives having agonist-like activity at alpha 2B or 2B/2C adrenergic receptors |
| 04/28/2004 | EP1413295A1 Sustained release composition for oral administration of drugs |
| 04/28/2004 | EP1412529A2 Methods for assessing the risk of obesity based on allelic variations in the 5'-flanking region of the insulin gene |
| 04/28/2004 | EP1412385A2 Modified insulin with reduced immunogenicity |
| 04/28/2004 | EP1412357A1 Beta-amino tetrahydroimidazo(1,2-a)pyrazines and tetrahydrotriazolo(4,3-a)pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 04/28/2004 | EP1412338A1 1,3,5-triazine-2,4,6-triones, preparation and use as gonadotropin-releasing hormone receptor antagonists |
| 04/28/2004 | EP1412330A1 Piperidine derivatives useful as modulators of chemokine receptor activity |
| 04/28/2004 | EP1411984A2 Combination medicament for treatment of neoplastic diseases which contains cyanoguanidine ikk inhibitors and a second anti-neoplastic drug |
| 04/28/2004 | EP1411945A1 Substituted pyridin-4-ones and their use as gonadotropin-releasing hormone receptor antagonists |
| 04/28/2004 | EP1411941A2 Pyridinone and pyridazinone derivatives as gonadotropin-releasing hormone receptor antagonists |
| 04/28/2004 | EP1411922A1 Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins |
| 04/28/2004 | EP1411907A1 Inhibitors of hb-egf (erbb) receptors for treating myeloma |
| 04/28/2004 | EP1411898A1 Pharmaceutical composition comprising lipids with a polar and a nonpolar moiety |
| 04/28/2004 | EP1137631B1 REVERSIBLE AQUEOUS pH SENSITIVE LIPIDIZING REAGENTS, COMPOSITIONS AND METHODS OF USE |
| 04/28/2004 | EP1087970B1 PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS |
| 04/28/2004 | CN1492930A Anti-interferon-šŒantibodies |
| 04/28/2004 | CN1492872A Tricycle quinolinone and tricycle quinoline as androgen receptor modulator compounds |
| 04/28/2004 | CN1492870A Xanthine derivative, production and use thereof as a medicament |
| 04/28/2004 | CN1492869A Tricyclic androgen receptor modulator compounds and method |
| 04/28/2004 | CN1491720A Inducer of blood vessel neogenesis |
| 04/28/2004 | CN1147301C Progestin therapy with controlled bleeding |
| 04/27/2004 | US6727392 Such as 4b(s)-benzyl-7(s)-hydroxy-7(s)-(3,3,3-trifluoropropyl)4,5,6,7,8,8a(r),9,10 -octahydro-phenanthrene-2-carboxylic acid (2-methyl-pyridin-3-ylmethyl)-amide via catalytic reduction; transcription factors |
| 04/27/2004 | US6727346 Obtaining insulin precursors; generate suspension of insulin and cysteine hydrochloride, heat, recover insulin precursors |
| 04/27/2004 | US6727273 Therapy for osteoporosis, anticancer agents |
| 04/27/2004 | US6727269 Acromegaly, pituitary adenoma or endocrine gastroenteropanceatic tumors including the carcinoid syndrome, and gastrointestinal bleeding |
| 04/27/2004 | US6727258 Allosteric adenosine receptor modulators |
| 04/27/2004 | US6727251 Inhibitors of glycogen synthase kinase-3 (gsk-3) and aurora-2, both serine/threonine protein kinases; for treating diseases such as cancer, diabetes and alzheimer's disease |
| 04/27/2004 | US6726918 Implanting bioerodible particle comprising steroidal antiinflammatory agent and polymer that delivers dexamethasone to vitreous; ophthalmology; uveitis, vision defects |
| 04/22/2004 | WO2004017948A3 Use of lck inhibitor for treatment of immunologic diseases |
| 04/22/2004 | WO2004005310A3 New compounds, compositions and methods for treatment of inflammatory diseases and conditions |
| 04/22/2004 | WO2003102012A3 New etonogestrel esters |
| 04/22/2004 | WO2003101958A3 Flourinated cyclic amides as dipeptidyl peptidase iv inhibitors |
| 04/22/2004 | WO2003087318A9 Truncated 24 kda basic fibroblast growth factor |
| 04/22/2004 | US20040077875 (5-(((2,4,6-Trimethylphenyl)amino)carbonyl)-4-methyl-2 -thiazolyl)carbamic Acid, 1,1-dimethylethyl ester for example; treating immunological and oncological disorders such as inflammatory bowel disease or cancer |
| 04/22/2004 | US20040077780 Thermogelling oligopeptide polymers |
| 04/22/2004 | US20040077730 Carbocyclic halo amines such as N,N-dimethyl-1-(1-(4-chloro-phenyl)cyclobutyl)-3-methylbutyl amine hydrochloride, used for reducing insulin resistance in humans having diabetes |